Status:
COMPLETED
Impact of Donor-Specific Antibodies in (Highly-) Immunized Living Donor Kidney Transplant Recipients
Lead Sponsor:
Erasmus Medical Center
Conditions:
Renal Failure
Eligibility:
All Genders
18-100 years
Brief Summary
Kidney transplantation is the preferred treatment for end-stage renal disease. Alongside limited availability of donors, rejection and premature graft loss are main barriers to kidney transplantation....
Eligibility Criteria
Inclusion
- Pre-transplantation donor-specific antibodies in Luminex Single Antigen Bead analysis.
- Age 18 years or older
Exclusion
- Desensitization treatment for a current or historic positive CDC-crossamtch
Key Trial Info
Start Date :
January 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
252 Patients enrolled
Trial Details
Trial ID
NCT05431712
Start Date
January 1 2010
End Date
December 31 2019
Last Update
February 20 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.